Formulation Design, Development of Gastro Retentive Floating Tablets of Propranolol

Main Article Content

D. Saritha

Abstract

Aim: The present research work was carried out by formulate and evaluate the gastro-retentive floating tablets of propranolol. Materials and Methods: Propranolol HCl is an antihypertensive agent. It is mainly used in the treatment of acute myocardial infarctions. Consequently, the current exploration was to design a gastro-retentive drug delivery system of propranolol using swelling polymer through wet granulation method. All the formulations were evaluated for weight variation, hardness, friability, drug content, and in-vitro dissolution. In this gastro-retentive dosage form using hydroxypropylmethylcellulose-K4M (HPMC-K4M) was prepared to develop a sustain release tablets, which could retain in the stomach for longer periods of time delivering the drug to the site of action that is in the stomach. Statistical Analysis used: Fourier-transform infrared signifying compatibility of the drug and polymers in the tablet composition. Results: Pre- and Post-compression parameters of all the formulations were within the pharmacopoeial limits and in-vitro drug release of F2 formulation was found to be 99.14% in 12 h. Conclusion: Dissolution studies of the composition, it was concluded that the formulation F2 which is containing 50 mg of HPMC-K4M, 25 mg of sodium bicarbonate, 25 mg of polyvinylpyrrolidone K30, 1.5 mg of magnesium stearate, and 1.5 mg of Talc is the best formulation. F2 possessed quick buoyancy lag time of 40 s and good total floating time of 12 h. As the consequence of this study, it may accomplish that the floating tablets using HPMC-K4M are a hydrophilic polymer increases the gross register tonnage of the dissolution fluid in the stomach to deliver the drug in a sustained manner.

Downloads

Download data is not yet available.

Article Details

How to Cite
Saritha, D. (2018). Formulation Design, Development of Gastro Retentive Floating Tablets of Propranolol. Asian Journal of Pharmaceutics (AJP), 12(02). https://doi.org/10.22377/ajp.v12i02.2425
Section
ORIGINAL ARTICLES